Gilead Will Study Emtriva Skin Discoloration Significance In Phase IV Trial
Executive Summary
The clinical significance of skin discoloration associated with Emtriva use is among the studies Gilead will do as part of its postmarketing commitments for the product
You may also be interested in...
Gilead Emtriva Marketing For HIV Will Highlight Long Intracellular Half-Life
Gilead Sciences' is highlighting Emtriva's long intracellular half-life as a distinguishing feature in the nucleoside reverse transcriptase inhibitor market for HIV therapy
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials